MedTrace Logo

Registry of Amyloid Positive Patients for Alzheimer's Disease Drug Research Trials

NCT02918539 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 317

Last updated 2018-10-24

No results posted yet for this study

Summary

This registry will be used to identify patients who have etiology diagnosed or suspected to be Alzheimer's disease and positive amyloid scans, and have indicated their interest in being contacted for an Eli Lilly and Company (Lilly) Alzheimer's Disease drug research trial.

Conditions

  • Alzheimer Disease
  • Cognition Disorders

Interventions

DRUG

florbetapir F 18 PET scan

For those patients who do not have an existing amyloid scan, each will receive an IV injection, 370 MBq (10 mCi), single dose of florbetapir F 18 followed by a Positron Emission Tomography (PET) Scan to determine amyloid status

Sponsors & Collaborators

  • Eli Lilly and Company

    collaborator INDUSTRY

  • PRA Health Sciences

    collaborator INDUSTRY

  • Avid Radiopharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Chief Medical Officer · Avid Radiopharmaceuticals, Inc.

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-31
Primary Completion
2017-10-18
Completion
2017-10-18

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02918539 on ClinicalTrials.gov